Trial Status: Enrollment and study of participants in this trial have both been completed. The sponsor and the Huntington Study Group investigators are in process of analyzing results.

Trial name: REACH2HD

FDA phase: Phase II

Sponsor: Prana Biotechnology Limited

Trial design: Double blind placebo controlled

Outcome measures: Primary: Safety and tolerability. Multiple secondary measures including cognitive, motor, behavioral and functional abilities.

Location: Multiple sites in North America and Australia